drugset / Trial / NCT01761214

Bacteriology and Inflammation in Bronchiectasis

NCT01761214

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Bronchiectasis is a chronic disease arises from progressive airway inflammation and infection. It has been postulated that bacterial infection triggers intense airway inflammation leading to acute exacerbation of bronchiectasis. Antibiotics have been the most potent medications for the treatment of bronchiectasis, however, the sputum bacterial load and inflammatory indices at steady-state and exacerbation remain largely unknown. The investigation might shed light on the roles that antibiotics play in acute exacerbation of bronchiectasis and uncover the mechanisms on why a subgroup of individuals do not respond satisfactorily.

Timeline

Start
2012-09
Primary completion
2023-12
Completion
2023-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Amoxicillin Other / unclassified
Comparator Ciprofloxacin Small molecule 500 mg
Comparator Levofloxacin Small molecule 500 mg Oral
Comparator Moxifloxacin Small molecule 400 mg
Comparator amoxicillin clavulanate potassium compound Unknown

Indications